Načítá se...
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to...
Uloženo v:
| Vydáno v: | Psoriasis (Auckl) |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717840/ https://ncbi.nlm.nih.gov/pubmed/31696051 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S161453 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|